BLUE Hit By SCD Trial Blues, CRTX Plunges On Partial Hold, SESN To Face FDA In August

(RTTNews) – Today’s Daily Dose brings you news about temporary suspension of bluebird bio’s gene therapy trials in sickle cell disease, Sesen Bio’s regulatory catalyst for this year, partial hold on Cortexyme’s open-label extension phase of its ongoing phase II/III study of AtuzaRead MoreMarketsMarkets Feed